Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands

Journal of Inflammation

Volumn 46, Issue 4, 1995, Pages 220-234

  Hochman, Paula S ^a  

^a Biegen Inc   (United States)

Author keywords

inflammation; lymphotoxin; receptor crosslinking; TNF receptors

Indexed keywords

GALACTOSAMINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR CELL LINE;

ANIMALS; CELL ADHESION MOLECULES; CELL DIVISION; CELL SURVIVAL; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; LYMPHOTOXIN BETA RECEPTOR; MICE; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029521971     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Vassalli P: The pathophysiology of tumor necrosis factors. Ann Rev Immunol 10:411-452, 1992.
2. Liu A, Miskovsky EP, Stanhope PE, Siliciano RF: Production of transmembrane and secreted forms of tumor necrosis factor (TNF-a) by HIV-1-specific CD4+ cytolytic T lymphocyte clones. J Immunol 148:3789-3798, 1992.
3. Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic trans-membrane protein: ramifications for the complex physiology of TNF. Cell 53:45-53, 1988.
4. Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, Benjamin CP, Hession C: Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol 154:33-46, 1995.
5. Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP, Hession C, O'Brine GB, Foley SF, Ware C.: Lymphotoxin , a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72:847-856, 1993.
6. Androlewicz MJ, Browning JL, Ware CF: Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J Biol Chem 267:2542-2547, 1992.
7. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL: Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881-3888, 1992.
8. Browning JL, Androlewicz MJ, Ware CF: Lymphotoxin a and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma. J Immunol 147:1230-1237, 1991.
9. Eck MJ, Sprang S: The structure of TNFa at 2.6 A resolution. Implications for receptor binding. J Biol Chem 264:17595-17605, 1989.
10. Eck MJ, Ultsch M, Rinderknecht E, de Vos AM, Sprang SR: The structure of human lymphotoxin (tumor necrosis factor-) at 1.9-A resolution. J Biol Chem 267:21192122, 1992.
11. Jones E, Stuart D, Walker, N: Structure of TNF. Nature 338:225-228, 1989.
12. Smith RA, Baglioni C: The active form of tumor necrosis factor is a trimer. J Biol Chem 262:6951-6954, 1987.
13. Browning J, Ribolini A: Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines. J Immunol 143:1859-67, 1989.
14. Goh C: Protein engineering of tumour necrosis factor and its applications in cancer, septicemia and cachexia. Ann Acad Medicine Singapore 22:651-656, 1993.
15. Wingfield P, Pain RH, Craig S: Tumor necrosis factor is a compact trimer. FEBS Letters 211:179-184, 1987.
16. Schoenfeld HJ, Poeschl B, Frey JR, Loetscher H, Hunziker W, Lustig A, Zulauf M: Efficient purification of recombinant human tumor necrosis factor beta from Escherichia coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors. J Biol Chem 266:3863-3869, 1991.
17. Pennica D, Lam VT, Weber RF, Kohr WJ, Basa LJ, Spellman MW, Ashkenazi A, Shire SJ, Goeddel DV: Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry 32:3131-3138, 1993.
18. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W: Human tumor necrosis factor alpha (TNFa) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 268:26350-26357, 1993.
19. Goh CR, Loh CS, Porter AG: Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor (lymphotoxin). Protein Eng 4:785-791, 1991.
20. Goh CR, Porter AG: Structural and functional domains in human tumour necrosis factors. Protein Eng 4:385389,1991.
21. van Ostade S, Tavernier J, Prange T, Fiers W: Localisation of the active site of human tumor necrosis factor by mutational analysis. EMBO 10:827-836, 1991.
22. Yamagishi J-l, Kawashima H, Matsuo N, Ohue M, Yamayoshi M, Fukui T, Kotani H, Furuta R, Nakano K, Yamada M: Mutational analysis of structure-activity relationships in human tumor necrosis factor-a Protein Engineering 3:713-719, 1990.
23. Ware CF, van Arsdale TL, Crowe PD, Browning JL: The ligands and receptors of the lymphotoxin system. In Griffiths G, Tschopp J (eds): "Pathways for Cytolysis" in Current Topics Microbiol Immunol New York: SpringerVerlag, 1995, Vol. 198, pp 175-218.
24. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith ÇA: A lymphotoxin -specific receptor. Science Wash DC 264:707-710, 1994.
25. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H: Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature Lond 364:798-802, 1993.
26. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Kronke M, Mak, TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L monocytogenes infection. Cell 73:457-467, 1993.
27. Erickson SL, de Sauvage FJ, Kikly K Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore M: Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372:560-563, 1994.
28. De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SS, Carlson R, Shornick LP, Strauss-Schoenberger J, Russell JH, Karr R, Chaplin DD: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264:703707, 1994.
29. Banks TA, Rouse BT, Kerley MK, Blair PJ, Godfrey VL, Kuklin NA, Bouley DM, Thomas J, Kanangat S, Mucenski ML: Lymphotoxin-ot-deficient mice: Effects on secondary lymphoid development and humoral immune responsiveness. J Immunol 155:16851693, 1995.
30. Browning JL, Miatkowski K, Dougas-Sizing I, Griffiths DA, Zafari M, Benjamin CP, Meier W, Mackay F: Signalling through the lymphotoxin- receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 183: 867-878, 1996.
31. Crowe PD, VanArsdale TL, Walter BN, Dahms KM, Ware CF: Production of lymphotoxin (LTot) and a soluble dimeric form of its receptor using the baculovirus expression system. J Immunol Methods 168:79-89, 1994.
32. Browning JL, Miatkowski K, Griffiths DA, Bourdon PR, Hession C, Ambrose CM, Meier W: Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta. J Biol Chem, 271:8618-8626, 1996.
33. Gimbrone Jr MA: Culture of vascular endothelium. Hemost Thromb 3:1, 1976.
34. Thornton SC, Mueller SN, Levine EM: Human endothelial cells: Use of heparin in cloning and long-term serial cultivation. Science Wash DC 222:623-625, 1983.
35. Lobb RR, Chi-Rosso G, Leone DR, Rosa MD, Bixler S, Newman BN, Luhowskyj S, Benjamin CD, Dougas I, Goelz SE, Hession C, Chow EP: Expression and functional characterization of a soluble form of endothelialleukocyte adhesion molecule-1. J Immunol 147:124-129, 1991.
36. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59:1203-1211, 1989.
37. Digman JD, Lebowitz RM, Boeder RG: Accurate transcription initiation by RIMA polymerase II in soluble extract from isolated mammalian nuclei. Nucleic Acids Research 11:1475-1489, 1983.
38. Mackay F, Loetscher H, Stueber D, Gehr G, Lesslauer W: Tumor necrosis factor alpha (TNF-oc)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177:1277-86, 1993.
39. Osborn L, Kundel S, Nabel GJ: Tumor necrosis factor a and interleukin 1 stimulate human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sei USA 86:2336-2340, 1989.
40. Lowenthal JW, Ballard DW, Bohnlein E, Greene WC: Tumor necrosis factor a induces proteins that bind specifically to icB-like enhancer elements and regulate interleukin 2 receptor ex-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sei USA 86:2331-2335, 1989.
41. Lehmann V, Freudenberg MA, Galanos C: Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J Exp Med 165:657-663, 1987.
42. van Ostade X, Tavernier J, Fiers W: Structure-activity studies of human tumour necrosis factors. Protein Engineering 7:5-22, 1994.
43. Force WR, Walter BN, Hession C, Tizard R, Kozak CA, Browning JL, Ware CF: Mouse lymphotoxin- receptor-molecular genetics, ligand binding and expression. J Immunol 155:5280-5288, 1995.
44. Qin Z, van Tits LJH, Buurman WA, Blankenstein T: Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice. Blood 85:2779-2785, 1995.
45. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, Bevilacqua MP, Mendrick DL, Gimbrone Jr MA: Activation of cultured human endothelial cells by recombinant lymphotoxin: Comparison with tumor necrosis factor and interleukin 1 species. J Immunol 138:3319-3324, 1987.
46. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kolias G, Pfizenmaier K, Scheurich P: The transmembrane form of tumor necrosis factor is the prime activating ligand of the SOkDa tumor necrosis factor receptor. Cell 83:793-802.
47. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W: Crystal structure of the soluble human 55 kd TNF receptor-human TNF complex: Implications for TNF receptor activation. Cell 73:431-445, 1993.
48. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR: Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 270:13303-13307, 1995.
49. Tartaglia LA, Goeddel DV: Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 267:4304-4307, 1992.
50. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas 0, Leitner O, Wallach D: Antibodies to a soluble form of a tumor necrosis factor receptor have TNF-like activity. J Biol Chem 265:1449714504, 1990.
51. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, EspevikT: Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 172:1517-1520, 1990.
52. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MJ, Goeddel DV: The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sei USA 88:9292-9296, 1991.
53. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Sha-laby R: Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med 171:415-426,1989.
54. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, Wallach C: Self-association of the "Death Domains" of the p55 tumor necrosis factor receptor and Fas/AP01 prompts signaling for TNF and Fas/APOl effects. J Biol Chem 270:387-391, 1995.